CN106336457B - Identify the φt cell receptor of MAGE A3 antigen small peptides - Google Patents
Identify the φt cell receptor of MAGE A3 antigen small peptides Download PDFInfo
- Publication number
- CN106336457B CN106336457B CN201510733891.6A CN201510733891A CN106336457B CN 106336457 B CN106336457 B CN 106336457B CN 201510733891 A CN201510733891 A CN 201510733891A CN 106336457 B CN106336457 B CN 106336457B
- Authority
- CN
- China
- Prior art keywords
- tcr
- seq
- chains
- exons
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a kind of φt cell receptor (TCR) that can specifically bind the small peptide SYVKVLHHM derived from MAGE A3 antigens, the antigen small peptide SYVKVLHHM can with HLA A2402 formed compound and together be presented to cell surface.Present invention also offers encode the nucleic acid molecules of the TCR and include the carrier of the nucleic acid molecules.In addition, present invention also offers the cell for the TCR of the present invention that transduces.
Description
Technical field
The present invention relates to that can identify the TCR from MAGE-A3 antigen small peptides, the invention further relates to transduceing, above-mentioned TCR is obtained
The specific T cells of MAGE-A3, and their purposes in MAGE-A3 relevant diseases are prevented and treated.
Background technology
MAGE-A3 is degraded to micromolecule polypeptide as a kind of autochthonous tumor antigen after generating in the cell, and with
MHC (main histocompatibility complex) molecule combines to form compound, is presented to cell surface.Studies have shown that SYVKVLHHM
It is the small peptide derived from MAGE-A3.MAGE-A3 albumen has expression, including melanoma, Yi Jiqi in kinds of tumors type
His solid tumor such as stomach cancer, lung cancer, cancer of the esophagus, carcinoma of urinary bladder, head and neck squamous cell carcinoma etc..Treatment for above-mentioned disease, can
The methods of with using chemotherapy and radiation treatment, but the normal cell of itself can all be caused damage.
T cell adoptive immunotherapy is that will there is specific reaction-ive T cell to be transferred in patient body target cell antigen,
It is set to be played a role for target cell.φt cell receptor (TCR) is a kind of memebrane protein on T cell surface, and it can be identified accordingly
The antigen small peptide of target cells.In immune system, pass through the specific TCR of antigen small peptide and small peptide-main histocompatbility
The combination of complex (pMHC compounds) triggers T cell to be directly physically contacted with antigen presenting cell (APC), then T cell
And both APC other cell membrane surface molecules just interact, cause a series of follow-up cell signal transmission and its
His physiological reaction, so that the T cell of different antigentic specificities plays immunological effect to its target cell.Therefore, this area skill
Art personnel, which are directed to isolating, has specific TCR to MAGE-A3 antigen small peptides, and the TCR is transduceed into T cell to obtain
There is specific T cell to MAGE-A3 antigen small peptides, so that they play a role in cellular immunotherapy.
The content of the invention
It is an object of the invention to provide a kind of φt cell receptor of identification MAGE-A3 antigen small peptides.
The first aspect of the present invention, there is provided a kind of φt cell receptor (TCR), the TCR can be with SYVKVLHHM-HLA
A2402 compounds combine.
In another preference, the TCR includes TCR α chains variable domains and TCR β chain variable domains, the TCR α chain variable domains
CDR3 amino acid sequence be ALQYSGAGSYQLT (SEQ ID NO:12)；And/or the CDR3 of the TCR β chain variable domains
Amino acid sequence is ASSDGPNTEAF (SEQ ID NO:15).
In another preference, 3 complementary determining regions (CDR) of the TCR α chain variable domains are：
α CDR1-NYSPAY (SEQ ID NO:10)
α CDR2-IRENEKE (SEQ ID NO:11)
α CDR3-ALQYSGAGSYQLT (SEQ ID NO:12)；And/or
3 complementary determining regions of the TCR β chain variable domains are：
β CDR1-MNHNS (SEQ ID NO:13)
β CDR2-SASEGT (SEQ ID NO:14)
β CDR3-ASSDGPNTEAF (SEQ ID NO:15)。
In another preference, the TCR includes TCR α chains variable domains and TCR β chain variable domains, the TCR α chain variable domains
For with SEQ ID NO:1 has the amino acid sequence of at least 90% sequence thereto；And/or the TCR β chains variable domain be with
SEQ ID NO：5 have the amino acid sequence of at least 90% sequence thereto.
In another preference, the TCR includes α chain variable domain amino acid sequence SEQ ID NO:1.
In another preference, the TCR includes β chain variable domain amino acid sequence SEQ ID NO:5.
In another preference, the TCR is α β heterodimers, and it includes TCR α chain constant region TRAC*01 and TCR β
Chain constant region TRBC1*01 or TRBC2*01.
In another preference, the α chain amino acid sequences of the TCR are SEQ ID NO：3 and/or TCR β chain ammonia
Base acid sequence is SEQ ID NO:7.
In another preference, the TCR is solvable.
In another preference, the TCR is single-stranded.
In another preference, the TCR is to be formed by connecting by α chains variable domain with β chains variable domain by peptide catenation sequence.
In another preference, the TCR is in α chains variable region amino acid the 11st, 13,19,21,53,76,89,91 or
94, and/or α chain J gene small peptides amino acid is reciprocal 3rd, it is one or more prominent to have in 5th reciprocal or reciprocal 7th
Become；And/or the TCR β chains variable region amino acid the 11st, 13,19,21,53,76,89,91 or the 94th, and/or β chains J
Gene small peptide amino acid is reciprocal 2nd, has one or more mutation, wherein amino acid position in 4th reciprocal or reciprocal 6th
Numbering is put by the Position Number listed in IMGT (international immunogenetics information system).
In another preference, the α chains variable domain amino acid sequence of the TCR includes SEQ ID NO:32 and/or described
TCR β chains variable domain amino acid sequence includes SEQ ID NO:34.
In another preference, the amino acid sequence of the TCR is SEQ ID NO:30.
In another preference, the TCR includes all or part of TCR α chains (a) in addition to membrane spaning domain；And
(b) all or part of TCR β chains in addition to membrane spaning domain；
(a) and (b) each self-contained functional variable domain, and or include functional variable domain and the TCR
At least a portion of chain constant domain.
In another preference, cysteine residues form artificial disulfide bond between α the and β chain constant domains of the TCR.
In another preference, the cysteine residues that artificial disulfide bond is formed in the TCR instead of selected from following
One or more groups of sites：
The Ser57 of Thr48 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Ser17 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Asp59 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；
The Ala19 of Pro89 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；With
The Glu20 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s.
In another preference, the α chain amino acid sequences of the TCR are SEQ ID NO:26 and/or TCR β chains
Amino acid sequence is SEQ ID NO:28.
In another preference, artificial interchain disulfide bond is contained between the α chains variable region of the TCR and β chain constant regions.
In another preference, it is characterised in that the cysteine residues of artificial interchain disulfide bond are formed in the TCR
It instead of and be selected from following one or more groups of sites：
TRAV the 46th amino acids and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s；
TRAV the 47th amino acids and 61 amino acids of TRBC1*01 or TRBC2*01 exons 1s；
TRAV the 46th amino acids and the 61st amino acids of TRBC1*01 or TRBC2*01 exons 1s；Or
TRAV the 47th amino acids and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s.
In another preference, the TCR includes α chains variable domain and β chains variable domain and in addition to membrane spaning domain
All or part of β chains constant domain, but it does not contain α chain constant domains, α chains variable domain and the β chains of the TCR form heterogeneous dimerization
Body.
In another preference, the α chains of the TCR and/or C- the or N- ends of β chains are combined with conjugate.
In another preference, the conjugate that is combined with the φt cell receptor is detectable, therapeutic agent, PK are repaiied
Decorations part or the combination of these any materials.Preferably, the therapeutic agent is anti-CD 3 antibodies.
The second aspect of the present invention, there is provided a kind of multivalent TCR complex, it includes at least two TCR molecules, and its
In at least one TCR molecules be the TCR described in first aspect present invention.
The third aspect of the present invention, there is provided a kind of nucleic acid molecules, the nucleic acid molecules, which include, encodes first party of the present invention
The nucleotide sequence or its complementary series of TCR molecules described in face.
In another preference, the nucleic acid molecules include the nucleotide sequence SEQ ID NO of coding TCR α chain variable domains：
2 or SEQ ID NO:33.
In another preference, described nucleic acid molecules include the nucleotide sequence SEQ ID of coding TCR β chain variable domains
NO：6 or SEQ ID NO:35.
In another preference, the nucleic acid molecules include the nucleotide sequence SEQ ID NO of coding TCR α chains：4 and/or
Include the nucleotide sequence SEQ ID NO of coding TCR β chains：8.
The fourth aspect of the present invention, there is provided a kind of carrier, described carrier contain the core described in third aspect present invention
Acid molecule；Preferably, described carrier is viral vector；It is highly preferred that described carrier is slow virus carrier.
The fifth aspect of the present invention, there is provided a kind of host cell of separation, the present invention is contained in described host cell
The nucleic acid molecules described in the third aspect present invention of external source are integrated with carrier or genome described in fourth aspect.
The sixth aspect of the present invention, there is provided a kind of cell, the nucleic acid described in the cell transduction third aspect present invention
Carrier described in molecule or fourth aspect present invention；Preferably, the cell is T cell or stem cell.
The seventh aspect of the present invention, there is provided a kind of pharmaceutical composition, the composition contain pharmaceutically acceptable load
The TCR compounds described in TCR, second aspect of the present invention, third aspect present invention institute described in body and first aspect present invention
Carrier described in the nucleic acid molecules stated, fourth aspect present invention or the cell described in sixth aspect present invention.
The eighth aspect of the present invention, there is provided φt cell receptor or second aspect of the present invention described in first aspect present invention
Nucleic acid molecules described in described TCR compounds, third aspect present invention, carrier or this hair described in fourth aspect present invention
The purposes of cell described in bright 6th aspect, for preparing the medicine for the treatment of tumour or autoimmune disease.
The ninth aspect of the present invention, there is provided a kind of method for treating disease, including apply and fit to the object for needing to treat
The TCR compounds described in φt cell receptor or second aspect of the present invention, the present invention the 3rd described in the first aspect present invention of amount
The carrier described in nucleic acid molecules, fourth aspect present invention described in aspect or the cell or this hair described in sixth aspect present invention
Pharmaceutical composition described in bright 7th aspect；
Preferably, described disease is tumour, and preferably described tumour includes melanoma, and other entity tumors are such as
Stomach cancer, lung cancer, cancer of the esophagus, carcinoma of urinary bladder, head and neck squamous cell carcinoma etc..
It should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the invention and have in below (eg embodiment)
It can be combined with each other between each technical characteristic of body description, so as to form new or preferable technical scheme.As space is limited, exist
This no longer tires out one by one states.
Brief description of the drawings
Fig. 1 a, Fig. 1 b, Fig. 1 c, Fig. 1 d, Fig. 1 e and Fig. 1 f are respectively that TCR α chains variable domain amino acid sequence, TCR α chains are variable
Domain nucleotide sequence, TCR α chain amino acid sequences, TCR α chains nucleotide sequence, the TCR α chain amino acid sequences with targeting sequencing
And the TCR α chain nucleotide sequences with targeting sequencing.
Fig. 2 a, Fig. 2 b, Fig. 2 c, Fig. 2 d, Fig. 2 e and Fig. 2 f are respectively that TCR β chains variable domain amino acid sequence, TCR β chains are variable
Domain nucleotide sequence, TCR β chain amino acid sequences, TCR β chains nucleotide sequence, the TCR β chain amino acid sequences with targeting sequencing
And the TCR β chain nucleotide sequences with targeting sequencing.
Fig. 3 is the CD8 of monoclonal cell+And the double positive staining results of the tetramer-PE.
Fig. 4 a and Fig. 4 b are respectively the amino acid sequence and nucleotide sequence of sTCR α chains.
Fig. 5 a and Fig. 5 b are respectively the amino acid sequence and nucleotide sequence of sTCR β chains.
Fig. 6 is the glue figure of the sTCR obtained after purification.Leftmost side swimming lane is non-reduced glue, and middle swimming lane is molecule
Amount mark (marker), rightmost side swimming lane are to go back virgin rubber.
Fig. 7 a and Fig. 7 b are respectively single-stranded TCR amino acid sequence and nucleotide sequence.
Fig. 8 a and Fig. 8 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR α chains.
Fig. 9 a and Fig. 9 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR β chains.
Figure 10 a and Figure 10 b are respectively single-stranded TCR catenation sequences (l inker) amino acid sequence and nucleotide sequence.
Figure 11 is the soluble single-chain T CR obtained after purification glue figure.Left side swimming lane is molecular weight marker (marker), right
Breathing arm road is non-reduced glue.
Figure 12 is the BIAcore dynamics figures that sTCR of the present invention is combined with SYVKVLHHM-HLA A2402 compounds
Spectrum.
Figure 13 is that soluble single-chain T CR of the present invention moves with the BIAcore that SYVKVLHHM--HLA A2402 compounds are combined
Mechanics collection of illustrative plates.
Embodiment
The present inventor have found and MAGE-A3 antigen small peptide SYVKVLHHM (SEQ ID by in-depth study extensively
NO:9) TCR that can be specifically bound, the antigen small peptide SYVKVLHHM can with HLA A2402 formed compound and together with by
It is presented to cell surface.Present invention also offers encode the nucleic acid molecules of the TCR and include the carrier of the nucleic acid molecules.
In addition, present invention also offers the cell for the TCR of the present invention that transduces.
Term
MHC molecule is the protein of immunoglobulin superfamily, can be I class or class Ⅱ[MHC.Therefore, its for
The presentation of antigen has specificity, and different individuals has different MHC, can present small peptide different in a kind of proteantigen to respectively
From APC cell surfaces.The MHC of the mankind is commonly referred to as HLA genes or HLA complexs.
φt cell receptor (TCR), it is the unique of specific antigen peptide of the presentation in main histocompatibility complex (MHC)
Acceptor.In immune system, trigger T cell and antigen presentation thin by the combination of the TCR and pMHC compounds of antigentic specificity
Born of the same parents (APC) are directly physically contacted, and then both T cell and APC other cell membrane surface molecules just interact, this
A series of follow-up cell signal transmission and other physiological reactions are just caused, so that the T cell of different antigentic specificities
Immunological effect is played to its target cell.
TCR is the glycoprotein of the cell membrane surface as existing for α chains/β chains or γ chains/δ chains in the form of heterodimer.
TCR heterodimers are made up of α and β chains in 95% T cell, and 5% T cell has the TCR being made up of γ and δ chains.My god
The right heterogeneous dimerization TCR of α β have α chains and β chains, and α chains and β chains form α β heterodimerics TCR subunit.In a broad sense, α and β
Each chain includes variable region, bonding pad and constant region, and β chains generally contain short variable region also between variable region and bonding pad, but
The variable region is often regarded as a part for bonding pad.Each variable region includes and is entrenched in frame structure (framework regions)
3 CDR (complementary determining region), CDR1, CDR2 and CDR3.CDR region determines the combination of TCR and pMHC compounds, wherein
CDR3 is formed by variable region and bonding pad restructuring, is referred to as hypervariable region.TCR α and β chains, which are typically regarded as, respectively to be had two " domains "
That is variable domain and constant domain, variable domain are made up of the variable region connected and bonding pad.The sequence of TCR constant domains can be exempted from the world
Found in the public database of epidemic disease genetics information system (IMGT), if the constant domain sequence of TCR molecule alpha chains is " TRAC*01 ",
The constant domain sequence of TCR molecule β chains is " TRBC1*01 " or " TRBC2*01 ".In addition, TCR α and β chains also comprising transmembrane region and
Cytoplasmic region, cytoplasmic region are very short.
In the present invention, term " polypeptide of the present invention ", " TCR " of the invention, " φt cell receptor of the invention " is interchangeable makes
With.
Native interchain disulfide bond and artificial interchain disulfide bond
One group of disulfide bond be present in natural TCR membrane-proximal region C α and C β interchain, be referred to as " the sulphur of native interchain two in the present invention
Key ".In the present invention, by what is be artificially introduced, the position interchain covalent disulfide bonds different from the position of native interchain disulfide bond claim
For " artificial interchain disulfide bond ".
For convenience of the position of description disulfide bond, TRAC*01 and TRBC1*01 or TRBC2*01 amino acid sequences in the present invention
Position Number by from N-terminal to C-terminal order successively carry out Position Number, in TRBC1*01 or TRBC2*01, by from N-terminal to
The 60th amino acid of the order of C-terminal successively is P (proline), then can describe it as TRBC1*01 or TRBC2*01 in the present invention
The Pro60 of exons 1, the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s can be also stated that, and for example
Be Q (glutamine) by the 61st amino acid of the order from N-terminal to C-terminal successively in TRBC1*01 or TRBC2*01, then it is of the invention
In can describe it as the Gln61 of TRBC1*01 or TRBC2*01 exons 1s, can also be stated that TRBC1*01 or TRBC2*
61st amino acids of 01 exons 1, other are by that analogy.In the present invention, variable region TRAV and TRBV amino acid sequence
Position Number, according to the Position Number listed in IMGT.Such as some amino acid in TRAV, the Position Number listed in IMGT is
46, then the amino acids of TRAV the 46th are described it as in the present invention, other are by that analogy.In the present invention, the sequence of other amino acid
Column position numbering has specified otherwise, then by specified otherwise.
Detailed description of the invention
TCR molecules
In antigen processing pathways, antigen is degraded in the cell, is then carried by MHC molecule to cell surface.T is thin
Born of the same parents' acceptor can identify the peptide-MHC compounds of Antigen Presenting Cell surface.Therefore, the first aspect of the present invention provides one kind
The TCR molecules of SYVKVLHHM-HLA A2402 compounds can be combined.Preferably, the TCR molecules are separation or purifying
's.α the and β chains of the TCR respectively have 3 complementary determining regions (CDR).
One in the present invention is preferably carried out in mode, and the α chains of the TCR are included with following amino acid sequence
CDR：
α CDR1-NYSPAY (SEQ ID NO:10)
α CDR2-IRENEKE (SEQ ID NO:11)
α CDR3-ALQYSGAGSYQLT (SEQ ID NO:12)；And/or
3 complementary determining regions of the TCR β chain variable domains are：
β CDR1-MNHNS (SEQ ID NO:13)
β CDR2-SASEGT (SEQ ID NO:14)
β CDR3-ASSDGPNTEAF (SEQ ID NO:15)。
The CDR region amino acid sequence of the invention described above can be embedded into chimeric to prepare in any suitable frame structure
TCR.As long as frame structure is compatible with the TCR of present invention CDR region, those skilled in the art are according to CDR region disclosed by the invention
It can just design or synthesize the TCR molecules with corresponding function.Therefore, TCR molecules of the present invention refer to include above-mentioned α and/or β
The TCR molecules of chain CDR region sequence and any suitable frame structure.TCR α chains variable domain of the present invention be and SEQ ID NO:1 tool
There is the amino acid sequence of at least 90%, preferably 95%, more preferably 98% sequence thereto；And/or TCR β chains of the present invention can
Variable domain be and SEQ ID NO：5 have at least 90%, preferably 95%, the amino acid sequence of more preferably 98% sequence thereto
Row.
In the preference of the present invention, TCR molecules of the invention are the heterodimers being made up of α and β chains.Specifically
Ground, the α chains of the one side heterogeneous dimerization TCR molecules include variable domain and constant domain, the α chains variable domain amino acid sequence bag
CDR1 (SEQ ID NO containing above-mentioned α chains：10)、CDR2(SEQ ID NO：And CDR3 (SEQ ID NO 11):12).Preferably,
The TCR molecules include α chain variable domain amino acid sequence SEQ ID NO:1.It is highly preferred that the α chain variable domains of the TCR molecules
Amino acid sequence is SEQ ID NO:1.On the other hand, the β chains of the heterogeneous dimerization TCR molecules include variable domain and constant domain,
The β chains variable domain amino acid sequence includes CDR1 (the SEQ ID NO of above-mentioned β chains:13)、CDR2(SEQ ID NO：14) and
CDR3(SEQ ID NO:15).Preferably, the TCR molecules include β chain variable domain amino acid sequence SEQ ID NO:5.It is more excellent
Selection of land, the β chains variable domain amino acid sequence of the TCR molecules is SEQ ID NO:5.
In the preference of the present invention, TCR molecules of the invention are part or all of and/or β chains the portions by α chains
The single chain TCR molecules for dividing or all forming.Description about single chain TCR molecules may be referred to document Chung et al (1994)
Proc.Natl.Acad.Sci.USA 91,12654-12658.According to document, those skilled in the art can be easily
Structure includes the single chain TCR molecules in CDRs areas of the present invention.Specifically, the single chain TCR molecules include V α, V β and C β, preferably
According to being linked in sequence from N-terminal to C-terminal.
The α chains variable domain amino acid sequence of the single chain TCR molecules includes CDR1 (the SEQ ID NO of above-mentioned α chains：10)、
CDR2(SEQ ID NO：And CDR3 (SEQ ID NO 11):12).Preferably, the single chain TCR molecules include α chain variable domain ammonia
Base acid sequence SEQ ID NO:1.It is highly preferred that the α chains variable domain amino acid sequence of the single chain TCR molecules is SEQ ID NO:
1.The β chains variable domain amino acid sequence of the single chain TCR molecules includes CDR1 (the SEQ ID NO of above-mentioned β chains：13)、CDR2
(SEQ ID NO：And CDR3 (SEQ ID NO 14)：15).Preferably, the single chain TCR molecules include β chain variable domain amino acids
Sequence SEQ ID NO:5.It is highly preferred that the β chains variable domain amino acid sequence of the single chain TCR molecules is SEQ ID NO:5.
In the preference of the present invention, the constant domain of TCR molecules of the invention is the constant domain of people.Art technology
Personnel know or can obtained by consulting the public database of pertinent texts or IMGT (international immunogenetics information system)
Obtain the constant domain amino acid sequence of people.For example, the constant domain sequence of TCR molecule alphas chain of the present invention can be " TRAC*01 ", TCR points
The constant domain sequence of sub- β chains can be " TRBC1*01 " or " TRBC2*01 ".The amino acid sequence provided in IMGT TRAC*01
The 53rd be Arg, be expressed as herein：The Arg53 of TRAC*01 exons 1s, other are by that analogy.Preferably, TCR of the present invention
The amino acid sequence of molecule alpha chain is SEQ ID NO:3, and/or the amino acid sequence of β chains is SEQ ID NO:7.
Naturally occurring TCR is a kind of memebrane protein, is stabilized by its transmembrane region.As immunoglobulin (antibody) is made
The same for antigen recognizing molecule, TCR, which can also be developed, applied to diagnosis and treatment, at this moment to be needed to obtain soluble TCR points
Son.Soluble TCR molecules do not include its transmembrane region.STCR has very extensive purposes, and it cannot be only used for studying TCR
With pMHC interaction, it is also possible to make the diagnostic tool of detection infection or the mark as autoimmunity disease.Similarly, may be used
Dissolubility TCR can be used to therapeutic agent (such as cytotoxin compounds or immunostimulating compound) being transported to presentation specificity
The cell of antigen, in addition, sTCR can also combine to redirect T cell with other molecules (e.g., anti-CD 3 antibodies), from
And make the cell of its targeting presentation specific antigen.The present invention also obtain have to MAGE-A3 antigen small peptides it is specific solvable
Property TCR.
To obtain sTCR, on the one hand, TCR of the present invention can be introduced between the residue of itself α and β chain constant domain
The TCR of artificial disulfide bond.Cysteine residues form artificial interchain disulfide bond between α the and β chain constant domains of the TCR.Half Guang
Histidine residue can be substituted in other amino acid residues of appropriate site in natural TCR to form artificial interchain disulfide bond.For example,
Substitute the Thr48 of TRAC*01 exons 1s and the Ser57 of substitution TRBC1*01 or TRBC2*01 exons 1s cysteine residues
To form disulfide bond.Cysteine residues are introduced to can also be to form other sites of disulfide bond：TRAC*01 exons 1s
Thr45 and TRBC1*01 or TRBC2*01 exons 1s Ser77；The Tyr10 and TRBC1*01 of TRAC*01 exons 1s or
The Ser17 of TRBC2*01 exons 1s；Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s
Asp59；The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；TRAC*01 exons 1s
Arg53 and TRBC1*01 or TRBC2*01 exons 1s Ser54；The Pro89 and TRBC1*01 of TRAC*01 exons 1s or
The Ala19 of TRBC2*01 exons 1s；Or Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s
Glu20.I.e. cysteine residues instead of above-mentioned α and any group of site in β chain constant domains.Can be in TCR constant domains of the present invention
One or more C-terminals truncate most 50 or most 30 or most 15 or most 10 or most 8 or less
Amino acid so that its include cysteine residues come reach missing natural disulphide bonds purpose, also can be by the way that day will be formed
The cysteine residues of right disulfide bond sport another amino acid to reach above-mentioned purpose.
As described above, the TCR of the present invention may be embodied between the residue of itself α and β chain constant domain the artificial disulfide bond introduced.
It should be noted that the artificial disulfide bond with or without introducing described above between constant domain, it is constant that TCR of the invention can contain TRAC
Domain sequence and TRBC1 or TRBC2 constant domain sequences.TCR TRAC constant domains sequence and TRBC1 or TRBC2 constant domain sequences can
Connected by the natural disulphide bonds being present in TCR.
To obtain sTCR, on the other hand, TCR of the present invention is additionally included in the TCR that its hydrophobic core region is undergone mutation,
The mutation in these hydrophobic core regions is preferably capable the stability-enhanced mutation for making sTCR of the present invention, such as in publication number
Described in patent document for WO2014/206304.Such TCR can undergo mutation in its following hydrophobic core position of variable domain：
(α and/or β chains) variable region amino acid the 11st, 13,19,21,53,76,89,91,94, and/or α chain J genes (TRAJ) small peptide
Amino acid position is reciprocal 3rd, 5,7, and/or β chain J gene (TRBJ) small peptides amino acid position is reciprocal 2nd, 4,6, wherein ammonia
The Position Number of base acid sequence is by the Position Number listed in international immunogenetics information system (IMGT).People in the art
Member knows above-mentioned international immunogenetics information system, and the amino acid residue that different TCR can be obtained according to the database exists
Position Number in IMGT.
The TCR that hydrophobic core region is undergone mutation in the present invention can be by α and the β chain of a flexible peptide chain link TCR can
Variable domain and the solvable single-stranded TCR of stability formed.It should be noted that in the present invention flexible peptide chain can be any suitable connection TCR α with
The peptide chain of β chain variable domains.The single chain soluble TCR such as built in the embodiment of the present invention 4, its α chain variable domain amino acid sequence
For SEQ ID NO:32, the nucleotides sequence of coding is classified as SEQ ID NO:33；β chains variable domain amino acid sequence is SEQ ID NO:
34, the nucleotides sequence of coding is classified as SEQ ID NO:35.
In addition, for stability, patent document 201510260322.4 is also disclosed in TCR α chains variable region and β
Artificial interchain disulfide bond is introduced between chain constant region can significantly improve TCR stability.Therefore, high-affinity of the invention
Artificial interchain disulfide bond can also be contained between TCR α chains variable region and β chain constant regions.Specifically, can in the α chains of the TCR
The cysteine residues that artificial interchain disulfide bond is formed between change area and β chain constant regions instead of：TRAV the 46th amino acids
With the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s；TRAV the 47th amino acids and TRBC1*01 or
61 amino acids of TRBC2*01 exons 1s；TRAV the 46th amino acids and the of TRBC1*01 or TRBC2*01 exons 1s
61 amino acids；Or TRAV the 47th amino acids and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s.It is preferred that
Ground, such TCR can include all or part of TCR α chains (I) in addition to its membrane spaning domain, and (II) removes its cross-film knot
All or part of TCR β chains beyond structure domain, wherein (I) and (II) variable domain comprising TCR chains and at least a portion is constant
Domain, α chains form heterodimer with β chains.It is highly preferred that such TCR can include α chains variable domain and β chains variable domain and
All or part of β chains constant domain in addition to membrane spaning domain, but it does not contain α chain constant domains, the α chain variable domains of the TCR
Heterodimer is formed with β chains.
The present invention TCR can also multivalence complex form provide.The present invention multivalent TCR complex include two,
Three, the four or more TCR of the present invention polymers that are combined and are formed, can such as be produced with p53 four dimerization domains
The tetramer, or multiple TCR of the present invention and another molecule with reference to and the compound that is formed.The TCR compounds of the present invention can be used for body
Outer or tracking in vivo or targeting present the cell of specific antigen, it can also be used to produce other multivalence TCR with such application and answer
The intermediate of compound.
The TCR of the present invention can be used alone, and can also be combined with conjugate with covalent or other modes, preferably with covalently side
Formula combines.The conjugate includes detectable and (for diagnostic purpose, presented wherein the TCR is used to detect
The presence of the cell of SYVKVLHHM-HLA A2402 compounds), therapeutic agent, PK (protein kinase) modified parts or it is any more than
The combination of these materials combines or coupling.
Detectable for diagnostic purposes includes but is not limited to：Fluorescence or luminous marker, radioactively labelled substance,
MRI (magnetic resonance imaging) or CT (x-ray tomography of electronic computer) contrast agent can produce detectable product
Enzyme.
The therapeutic agent that can be combined or be coupled with TCR of the present invention includes but is not limited to：1. radionuclide (Koppe etc.,
2005, metastasis of cancer comment (Cancer metastasi s reviews) 24,539)；2. biology poison (Chaudhary etc., 1989,
Natural (Nature) 339,394；Epel etc., 2002, Cancer Immunol and immunization therapy (Cancer Immunology and
Immunotherapy) 51,565)；3. cell factor such as IL-2 etc. (Gillies etc., 1992, NAS's proceeding
(PNAS) 89,1428；Card etc., 2004, Cancer Immunol and immunization therapy (Cancer Immunology and
Immunotherapy) 53,345；Hal in etc., 2003, cancer research (Cancer Research) 63,3202)；4. antibody Fc
Fragment (Mosquera etc., 2005, Journal of Immunology (The Journal Of Immunology) 174,4381)；5. antibody
ScFv fragments (Zhu etc., 1995, cancer International Periodicals (International Journal of Cancer) 62,319)；6. gold medal
Nano particle/nanometer rods (Lapotko etc., 2005, cancer communication (Cancer letters) 239,36；Huang etc., 2006, it is beautiful
Chemical Society of state magazine (Journal of the American Chemical Soc iety) 128,2115)；7. virion
(Peng etc., 2004, gene therapy (Gene therapy) 11,1234)；8. liposome (Mamot etc., 2005, cancer research
(Cancer research) 65,11631)；9. magnetic nanosphere；10. pro-drug activation enzymes are (for example, DT- diaphorases (DTD) or connection
Phenyl hydrolase-sample protein (BPHL))；11. chemotherapeutics (for example, cis-platinum) or any type of nano particle etc..
In addition, the TCR of the present invention can also be comprising the heterozygosis TCR being derived from more than a kind of species sequence.For example, grind
Study carefully display Muridae TCR can more effectively to express than people TCR in human T-cell.Therefore, TCR of the present invention can include people's variable domain
With the constant domain of mouse.The defects of this method is possible to trigger immune response.Therefore, when it is used for adoptive T cell treatment
There should be regulation scheme to carry out immunosupress, to allow to express the implantation of the T cell of Muridae.
It should be understood that amino acid name is represented using international single English alphabet or three English alphabets herein, amino
The corresponding relation of the single English alphabet and three English alphabets of sour title is as follows：Ala(A)、Arg(R)、Asn(N)、Asp(D)、Cys
(C)、Gln(Q)、Glu(E)、Gly(G)、His(H)、Ile(I)、Leu(L)、Lys(K)、Met(M)、Phe(F)、Pro(P)、Ser
(S)、Thr(T)、Trp(W)、Tyr(Y)、Val(V)。
Nucleic acid molecules
The second aspect of the present invention provides the nucleic acid molecules of coding first aspect present invention TCR molecules or part thereof, institute
It can be one or more CDR, the variable domain of α and/or β chains, and α chains and/or β chains to state part.
The nucleotide sequence for encoding first aspect present invention TCR molecule alpha chain CDR regions is as follows：
α CDR1-aactattctccagcatac (SEQ ID NO:16)
α CDR2-atacgtgaaaatgagaaagaa (SEQ ID NO:17)
α CDR3-gctcttcaatactctggggctgggagttaccaactcact (SEQ ID NO:18)
The nucleotide sequence for encoding first aspect present invention TCR molecule β chain CDR regions is as follows：
β CDR1-atgaaccataactcc (SEQ ID NO:19)
β CDR2-tcagcttctgagggtacc (SEQ ID NO:20)
β CDR3-gccagcagtgacgggccgaacactgaagctttc (SEQ ID NO:21)
Therefore, encoding the nucleotide sequence of the nucleic acid molecules of the present invention of TCR α chains of the present invention includes SEQ ID NO:16、SEQ
ID NO:17 and SEQ ID NO:18, and/or the nucleotide sequence of the nucleic acid molecules of the present invention of coding TCR β chains of the present invention includes
SEQ ID NO:19、SEQ ID NO:20 and SEQ ID NO:21.
The nucleotide sequence of nucleic acid molecules of the present invention can be it is single-stranded or double-stranded, the nucleic acid molecules can be RNA or
DNA, and can include or not comprising introne.Preferably, the nucleotide sequence of nucleic acid molecules of the present invention does not include introne
But polypeptide of the present invention can be encoded, such as encodes the nucleotide sequence bag of the nucleic acid molecules of the present invention of TCR α chain variable domains of the present invention
Include SEQ ID NO:2 and/or the nucleotide sequences of nucleic acid molecules of the present invention of coding TCR β chain variable domains of the present invention include SEQ
ID NO:6.Or encode the nucleotide sequences of the nucleic acid molecules of the present invention of TCR α chain variable domains of the present invention and include SEQ ID NO:
33 and/or the nucleotide sequences of nucleic acid molecules of the present invention of coding TCR β chain variable domains of the present invention include SEQ ID NO:35.More
Preferably, the nucleotide sequence of nucleic acid molecules of the present invention includes SEQ ID NO:4 and/or SEQ ID NO:8.Or the present invention
The nucleotides sequence of nucleic acid molecules is classified as SEQ ID NO:31.
It should be understood that due to the degeneracy of genetic code, different nucleotide sequences can encode identical polypeptide.Therefore, compile
Code book invention TCR nucleotide sequence can variant identical with the nucleotide sequence shown in accompanying drawing of the present invention or degeneracy.With
One of example in the present invention illustrates that " variant of degeneracy " refer to that coding has SEQ ID NO:1 protein sequence,
But with SEQ ID NO:The 2 differentiated nucleotide sequence of sequence.
Nucleotide sequence can be through codon optimization.Different cells is above different in the utilization of specific codon
, the codon in sequence can be changed to increase expression quantity according to the type of cell.Mammalian cell and various other
Biology codon usage table be well known to a person skilled in the art.
The present invention nucleic acid molecules full length sequence or its fragment generally can with but be not limited to PCR TRAPs, recombination method or
Artificial synthesized method obtains.At present, it is already possible to completely by chemical synthesis come obtain encoding TCR of the present invention (or its fragment,
Or derivatives thereof) DNA sequence dna.Then the DNA sequence dna can be introduced various existing DNA moleculars as known in the art (or
Such as carrier) and cell in.DNA can be coding strand or noncoding strand.
Carrier
The invention further relates to the carrier for the nucleic acid molecules for including the present invention, including expression vector that is, can in vivo or body
The construct of outer expression.Conventional carrier includes bacterial plasmid, bacteriophage and animals and plants virus.
Viral delivery systems include but is not limited to adenovirus vector, adeno-associated virus (AAV) carrier, herpesvirus vector,
Retroviral vector, slow virus carrier, baculovirus vector.
Preferably, the nucleotides of the present invention can be transferred in cell by carrier, such as in T cell so that the cell table
Up to the TCR of MAGE-A3 antigentic specificities.Ideally, the carrier should can in T cell continual high levels earth's surface
Reach.
Cell
The invention further relates to the present invention carrier or coded sequence through host cell caused by genetic engineering.The host
The nucleic acid molecules of the present invention are integrated with carrier or chromosome containing the present invention in cell.Host cell is selected from：Prokaryotic
And eukaryotic, such as Escherichia coli, yeast cells, Chinese hamster ovary celI etc..
In addition, present invention additionally comprises the cell of the TCR of expression present invention separation, particularly T cell.The T cell can spread out
The T cell from subject's separation is born from, or can be the mixed cellularity group separated from subject, such as periphery hemolymph is thin
The part of born of the same parents (PBL) group.Such as, the cell can be isolated from PMBC (PBMC), can be CD4+Helper cell
Or CD8+Cytotoxic T cell.The cell can be in CD4+Helper cell/CD8+In the mixing group of cytotoxic T cell.Typically
Ground, the cell can use antibody (e.g., anti-CD3 or anti-CD28 antibody) to activate, to allow them to easily receive to turn
Dye, such as transfected with the carrier comprising the nucleotide sequence for encoding TCR molecules of the present invention.
Alternatively, cell of the invention can also be or derived from stem cell, such as candidate stem cell (HSC).Gene is turned
Moving to HSC will not cause in cell surface expression TCR, because stem cell surface does not express CD3 molecules.However, when stem cell point
Turn to when migrating to the lymphoid precursor of thymus gland (lymphoid precursor), the expression of CD3 molecules will start in thymocyte
The surface expression introducing TCR molecules.
Have many methods be suitable for the DNA or RNA for encoding TCR of the present invention carry out T cell transfection (e.g., the such as Robbins,
(2008)J.Immunol.180:6116-6131).The T cell for expressing TCR of the present invention can be used for adoptive immunotherapy.Ability
Field technique personnel understand that many appropriate methods (e.g., the such as Rosenberg, (2008) Nat Rev for carrying out adoptive treatment
Cancer8(4)：299-308).
MAGE-A3 antigen-related diseases
The invention further relates to being treated in subject and/or preventing the method with MAGE-A3 relevant diseases, it includes adopting
Property transfer MAGE-A3 specific T-cells to the subject the step of.The MAGE-A3 specific T-cells can recognize that SYVKVLHHM-
HLA A2402 compounds.
The specific T cells of MAGE-A3 of the present invention can be used for treating any presentation MAGE-A3 antigen small peptides
The MAGE-A3 relevant diseases of SYVKVLHHM-HLA A2402 compounds.Including but not limited to tumour, such as melanoma, Yi Jiqi
His entity tumor such as stomach cancer, lung cancer, cancer of the esophagus, carcinoma of urinary bladder, head and neck squamous cell carcinoma etc..
Treatment method
Can be suffered from by separation with the patient of MAGE-A3 antigen-related diseases or the T cell of volunteer, and by the present invention
TCR import in above-mentioned T cell, then the cell that these genetic engineerings are modified is fed back in patient body to be treated.Cause
This, it is thin the invention provides a kind of method for treating MAGE-A3 relevant diseases, including by the expression TCR of the present invention of separation T
Born of the same parents, it is preferable that the T cell in itself, is input in patient body from patient.Usually, the T cell of (1) separation patient is included,
(2) with nucleic acid molecules of the present invention or the nucleic acid molecules ex vivo transduction T cells of TCR molecules of the present invention can be encoded, (3) are by gene work
The T cell of journey modification is input in patient body.The quantity of separation, transfection and the cell fed back can be determined by doctor.
Main advantages of the present invention are：
(1) TCR of the invention can be combined with MAGE-A3 antigen small peptide compound SYVKVLHHM-HLA A2402, simultaneously
The TCR of the present invention cell of having transduceed can have very strong lethal effect by specific activation and to target cell.
Following specific embodiment, is expanded on further the present invention.It should be understood that these embodiments be merely to illustrate the present invention and
It is not used in limitation the scope of the present invention.The experimental method of unreceipted actual conditions in the following example, generally according to normal condition,
Such as (Sambrook and Russell et al., molecular cloning：Laboratory manual (Molecular Cloning-A Laboratory
Manual) (third edition) (2001) CSHL publishing houses) described in condition, or according to the condition proposed by manufacturer.Unless
Explanation in addition, otherwise percentage and number are calculated by weight.Unless otherwise indicated, otherwise percentage and number are calculated by weight.
Experiment material and reagent used can obtain from commercially available channel unless otherwise instructed in following examples.
Embodiment 1 clones MAGE-A3 antigen small peptide specific T-cells
Using synthesizing small peptide SYVKVLHHM (SEQ ID NO.:9；Beijing SBS Genetech gene technology Co., Ltd) stimulate and
From in the PBLC (PBL) for the healthy volunteer that genotype is HLA A2402.By SYVKVLHHM small peptides with carrying
The HLA A2402 renaturation of biotin labeling, prepare pHLA monoploid.These monoploid and the Streptavidin (BD marked with PE
Company) tetramer of PE marks is combined into, sort the tetramer and anti-CD8-APC double positive cells.The cell of sorting is expanded,
And secondary sorting is carried out as stated above, then carry out monoclonal with limiting dilution assay.Monoclonal cell tetramer staining, sieve
The double positive colonies chosen are as shown in Figure 3.
Embodiment 2 obtains the tcr gene of MAGE-A3 antigen small peptide specific T-cell clones and the structure of carrier
Use Quick-RNATMThe antigen small peptide screened in MiniPrep (ZYMO research) extracting embodiments 1
The total serum IgE of SYVKVLHHM specificity, HLA A2402 restricted T cell clone.CDNA synthesis is using clontech's
SMART RACE cDNA amplification kits, the primer of use are designed in the C-terminal conserved region of mankind's tcr gene.Sequence is cloned
It is sequenced on to carrier T (TAKARA).It should be noted that the sequence is complementary series, not comprising introne.Through sequencing, this pair of sun
Property clonal expression TCR α chains and β chain-orderings structure respectively as depicted in figs. 1 and 2, Fig. 1 a, Fig. 1 b, Fig. 1 c, Fig. 1 d, Fig. 1 e
With Fig. 1 f be respectively TCR α chains variable domain amino acid sequence, TCR α chain variable domains nucleotide sequence, TCR α chain amino acid sequences,
TCR α chains nucleotide sequence, the TCR α chain amino acid sequences with targeting sequencing and the TCR α chain nucleotides with targeting sequencing
Sequence；Fig. 2 a, Fig. 2 b, Fig. 2 c, Fig. 2 d, Fig. 2 e and Fig. 2 f are respectively TCR β chains variable domain amino acid sequence, TCR β chain variable domains
Nucleotide sequence, TCR β chain amino acid sequences, TCR β chains nucleotide sequence, have targeting sequencing TCR β chain amino acid sequences with
And the TCR β chain nucleotide sequences with targeting sequencing.
Identified, α chains include the CDR with following amino acid sequence：
α CDR1-NYSPAY (SEQ ID NO:10)
α CDR2-IRENEKE (SEQ ID NO:11)
α CDR3-ALQYSGAGSYQLT (SEQ ID NO:12)
β chains include the CDR with following amino acid sequence：
β CDR1-MNHNS (SEQ ID NO:13)
β CDR2-SASEGT (SEQ ID NO:14)
β CDR3-ASSDGPNTEAF (SEQ ID NO:15)
The full-length gene of TCR α chains and β chains is cloned into by Lentiviral by overlapping (overlap) PCR respectively
pLenti(addgene).Specially：The full-length gene of TCR α chains and TCR β chains is attached to obtain TCR with overlap PCR
α -2A-TCR β fragments.Lentiviral and TCR α -2A-TCR β digestions are connected to obtain pLenti-TRA-2A-TRB-
IRES-NGFR plasmids.Used as control, while also construction expression eGFP slow virus carrier pLenti-eGFP.Use again afterwards
293T/17 packs pseudovirus.
The solvable TCR of the MAGE-A3 antigens small peptide of embodiment 3 specificity expression, refolding and purifying
To obtain solvable TCR molecules, α the and β chains of TCR molecules of the invention only can include its variable domain and portion respectively
Divide constant domain, and introduce a cysteine residues in the constant domain of α and β chains respectively to form artificial interchain disulfide bond,
The position for introducing cysteine residues is respectively the Ser57 of the Thr48 and TRBC2*01 exons 1s of TRAC*01 exons 1s；Its α
The amino acid sequence of chain is distinguished as shown in figures 4 a and 4b with nucleotide sequence, the amino acid sequence and nucleotide sequence of its β chain
Respectively as shown in figure 5 a and 5b, the cysteine residues of introducing with overstriking and underline alphabetical represent.Pass through《Molecular cloning
Laboratory manual》(Molecular Cloning a Laboratory Manual) (third edition, Sambrook and Russell)
Described in standard method above-mentioned TCR α and β chains objective gene sequence are inserted respectively into expression vector pET28a after synthesis
+ (Novagene), the cloning site of upstream and downstream is NcoI and NotI respectively.Insert Fragment confirms errorless by sequencing.
The expression vector of TCR α and β chains is converted by chemical transformation respectively and enters expression bacterium BL21 (DE3), bacterium
Grown with LB nutrient solutions, in OD600Induced when=0.6 with final concentration 0.5mM IPTG, the bag formed after TCR α and β chains expression
Contain body to be extracted by BugBuster Mix (Novagene), and through the repeated multiple times washing of BugBuster solution, forgive
Body is finally dissolved in 6M guanidine hydrochlorides, 10mM dithiothreitol (DTT)s (DTT), 10mM ethylenediamine tetra-acetic acids (EDTA), 20mM Tris (pH
8.1) in.
TCR α and β chains after dissolving are with 1：1 mass ratio is quickly mixed in 5M urea, 0.4M arginine, 20mM Tris
(pH 8.1), in 3.7mM cystamine, 6.6mM β-mercapoethylamine (4 DEG C), final concentration of 60mg/mL.Mixing
Solution is placed in dialysis (4 DEG C) in the deionized water of 10 times of volumes afterwards, deionized water is changed into buffer solution (20mM after 12 hours
Tris, pH 8.0) continue at 4 DEG C dialyse 12 hours.Solution after the completion of dialysis after 0.45 μM of membrane filtration, by the moon from
Sub- exchange column (HiTrap Q HP, 5ml, GE Healthcare) purifying.Eluting peak contains the successful α and β dimers of renaturation
TCR is confirmed by SDS-PAGE glue.TCR then by gel permeation chromatography (HiPrep 16/60, Sephacryl S-100HR,
GE Healthcare) it is further purified.TCR purity after purification is more than 90% by SDS-PAGE measure, and concentration is by BCA methods
It is determined that.The SDS-PAGE glue figures for the sTCR that the present invention obtains are as shown in Figure 6.
The specific soluble single-chain T CR of MAGE-A3 antigen small peptides of embodiment 4 generation
According to patent document WO2014/206304, using the method for rite-directed mutagenesis by TCR α and β in embodiment 2
The variable domain of chain has been built into the soluble single-chain T CR molecules of a stabilization with flexible small peptide (l inker) connection.This is single-stranded
Amino acid sequence and the nucleotide sequence difference of TCR molecules are as shown in figs. 7 a and 7b.The amino acid sequence of its α chain variable domain and
Nucleotide sequence difference is as figures 8 a and 8 b show；The amino acid sequence and nucleotide sequence of its β chain variable domain are respectively such as Fig. 9 a
Shown in Fig. 9 b；Amino acid sequence and the nucleotide sequence difference of its linker sequence are as as-shown-in figures 10 a and 10b.
By target gene through Nco I and the double digestions of Not I, it is connected with by the pET28a carriers of Nco I and the double digestions of Not I.
Connection product converts and to E.coli DH5 α, is coated with the LB flat boards containing kanamycins, 37 DEG C of inversion overnight incubations, positive gram of picking
It is grand enter performing PCR screening, positive recombinant is sequenced, determines that sequence correctly extracts recombinant plasmid transformed to E.coli afterwards
BL21 (DE3), for expressing.
The specific soluble single-chain T CR of MAGE-A3 antigen small peptides of embodiment 5 expression, renaturation and purifying
BL21 (DE 3) bacterium colony containing recombinant plasmid pET28a- template strands prepared in embodiment 4 is all inoculated in
In LB culture mediums containing kanamycins, 37 DEG C culture to OD600 be 0.6-0.8, addition IPTG to final concentration of 0.5mM, 37
DEG C continue to cultivate 4h.5000rpm centrifuges 15min harvesting sediments, is cracked with Bugbuster Master Mix (Merck)
Cell pellet, 6000rpm centrifugation 15min recovery inclusion bodys, then washed with Bugbuster (Merck) to remove cell
Fragment and membrane component, 6000rpm centrifugation 15min, collect inclusion body.By solubilization of inclusion bodies in buffer solution (20mM Tris-HCl
PH 8.0,8M urea) in, high speed centrifugation removes insoluble matter, and supernatant is standby in -80 DEG C of preservations with being dispensed after BCA standard measures
With.
In the single-stranded TCR inclusion body proteins dissolved to 5mg, 2.5mL buffer solutions (6M Gua-HCl, 50mM Tris- is added
HCl pH 8.1,100mM NaCl, 10mM EDTA), add DTT to final concentration of 10mM, 37 DEG C of processing 30min.With injection
Device is to 125mL renaturation buffers (100mM Tris-HClpH 8.1,0.4M L-arginines, 5M urea, 2mM EDTA, 6.5mM
β-mercapthoethylamine, 1.87mM Cystamine) in the single-stranded TCR after above-mentioned processing, 4 DEG C of stirrings are added dropwise
10min, renaturation solution is then loaded into the cellulose membrane bag filter that interception is 4kDa, bag filter is placed in the water of 1L precoolings, 4 DEG C
It is slowly stirred overnight.After 17 hours into, dialyzate changes to the buffer solution (20mM Tri s-HCl pH 8.0) of 1L precoolings, 4 DEG C after
Continuous dialysis 8h, then change dialyzate into identical fresh buffer and continue dialysed overnight.After 17 hours, sample is through 0.45 μm of filter
Membrane filtration, by anion-exchange column (HiTrap Q HP, GE Healthcare) after vacuum outgas, with 20mM Tris-
The 0-1M NaCl linear gradient elution liquid purifying proteins that HClpH 8.0 is prepared, the elution fraction of collection carry out SDS-PAGE points
Analysis, solvent resistant column (Superdex 75 10/300, GE are further used after the component concentration comprising single-stranded TCR
Healthcare) purified, target components also carry out SDS-PAGE analyses.
Elution fraction for BIAcore analyses further tests its purity using gel filtration.Condition is：Chromatographic column
Agi lent Bio SEC-3 (7.8 × 300mm of 300A, φ), mobile phase are 150mM phosphate buffers, flow velocity 0.5mL/
Min, 25 DEG C of column temperature, ultraviolet detection wavelength 214nm.
The SDS-PAGE glue figures for the soluble single-chain T CR that the present invention obtains are as shown in figure 11.
Embodiment 6, which combines, to be characterized
BIAcore is analyzed
Can be special with SYVKVLHHM-HLA A2402 compounds this example demonstrated the TCR molecules of the present invention of solubility
The opposite sex combines.
Detected using BIAcore T200 real-time analyzers the TCR molecules that are obtained in embodiment 3 and embodiment 5 with
The binding activity of SYVKVLHHM-HLA A2402 compounds.It is slow that the antibody (GenScript) of anti-Streptavidin is added into coupling
Fliud flushing (10mM sodium-acetate buffers, pH 4.77), then antibody is flowed through to the CM5 chips activated in advance with EDC and NHS, made
Antibody is fixed on chip surface, finally closes unreacted activating surface with the hydrochloric acid solution of monoethanolamine, completes coupling process, even
Connection horizontal about 15,000RU.
The Streptavidin of low concentration is set to flow through the chip surface of coated antibody, then by SYVKVLHHM-HLA
A2402 compounds flow through sense channel, and another passage is as reference channel, then by 0.05mM biotin with 10 μ L/min stream
Speed flows through chip 2min, closes the remaining binding site of Streptavidin.
The preparation process of above-mentioned SYVKVLHHM-HLA A2402 compounds is as follows：
A. purify
The E.col i bacterium solutions of 100ml induced expressions heavy chain or light chain are collected, 10ml is used after 4 DEG C of 8000g centrifuge 10min
PBS washing thallines are once, violent with 5ml BugBuster Master Mix Extraction Reagents (Merck) afterwards
Thalline is resuspended in concussion, and is rotated in room temperature and be incubated 20min, after 4 DEG C, 6000g centrifugation 15min, supernatant discarding, collection forgives
Body.
Above-mentioned inclusion body is resuspended in 5ml BugBuster Master Mix, room temperature rotation is incubated 5min；Add 30ml
The BugBuster of 10 times of dilution, mix, 4 DEG C of 6000g centrifuge 15min；Supernatant discarding, the BugBuster for adding 30ml to dilute 10 times
Inclusion body is resuspended, mixes, 4 DEG C of 6000g centrifuge 15min, are repeated twice, and add 30ml 20mM Tris-HCl pH 8.0 that bag is resuspended
Contain body, mix, 4 DEG C of 6000g centrifuge 15min, finally dissolve inclusion body, SDS-PAGE inspections with 20mM Tri s-HCl 8M urea
Inclusion body purity is surveyed, BCA kits survey concentration.
B. renaturation
The small peptide SYVKVLHHM (Beijing SBS Genetech gene technology Co., Ltd) of synthesis is dissolved in DMSO to 20mg/ml
Concentration.The inclusion body of light chain and heavy chain is dissolved with 8M urea, 20mM Tris pH 8.0,10mM DTT, is added before renaturation
3M guanidine hydrochlorides, 10mM sodium acetates, 10mM EDTA are further denatured.SYVKVLHHM peptides are added into renaturation with 25mg/L (final concentration)
Buffer solution (0.4M L-arginines, 100mM Tris pH 8.3,2mM EDTA, 0.5mM GSSGs, 5mM reduced forms
Glutathione, 0.2mM PMSF, are cooled to 4 DEG C), then sequentially add 20mg/L light chain and 90mg/L heavy chain (final concentration,
Heavy chain adds in three times, 8h/ times), renaturation carries out at least 3 days at 4 DEG C to completion, and can SDS-PAGE is detected renaturation success.
C. purified after renaturation
Make dialysis to change renaturation buffer with the 20mM Tris pH 8.0 of 10 volumes, at least change buffer solution and come twice
Fully reduce the ionic strength of solution.With 0.45 μm of cellulose acetate sheets filtration protein solution after dialysis, it is then loaded into
On HiTrap Q HP (GE General Electric Co. Limited) anion-exchange column (5ml bed volumes).Instrument (the general electricity of GE is purified using Akta
Gas company), the 0-400mM NaCl linear gradients liquid elution albumen that 20mM Tris pH 8.0 are prepared, pMHC is about in 250mM
Eluted at NaCl, collect all peak components, SDS-PAGE detection purity.
D. biotinylation
With Millipore super filter tubes by the pMHC molecular concentrations of purifying, while it is 20mM Tris pH by buffer exchange
8.0, then add biotinylation reagent 0.05M Bicine pH 8.3,10mM ATP, 10mM MgOAc, 50 μM of D-
Biotin, 100 μ g/ml BirA enzymes (GST-BirA), incubation at room temperature mixture are stayed overnight, and whether SDS-PAGE detections biotinylation
Completely.
E. the compound after purifying biological elementization
PMHC molecular concentrations after biotinylation is marked with Millipore super filter tubes are to 1ml, using gel permeation chromatography
The pMHC of purifying biological elementization, instrument (GE General Electric Co. Limited) is purified using Akta, with filtered PBS pre-equilibrations HiPrepTM
16/60 S200HR posts (GE General Electric Co. Limited), the concentrated biotinylation pMHC molecules of loading 1ml, then with PBS with
1ml/min flow velocitys elute.Biotinylated pMHC molecules occur in about 55ml as unimodal elution.Merging contains protein
Component, concentrated with Millipore super filter tubes, BCA methods (Thermo) measure protein concentration, add protease inhibitors
The packing of biotinylated pMHC molecules is stored in -80 DEG C by cocktail (Roche).
Using BIAcore Evaluation software computational dynamics parameters, obtain the TCR molecules of solubility of the invention with
And the kinetic profile point that the soluble single-chain T CR molecules of the invention built are combined with SYVKVLHHM-HLA A2402 compounds
Not as shown in Figure 12 and Figure 13.Collection of illustrative plates shows that the soluble TCR molecules and soluble single-chain T CR molecules that the present invention obtains are all
It can be combined with SYVKVLHHM-HLA A2402 compounds.Meanwhile also it have detected solubility of the invention using the above method
The binding activity of TCR molecules and other several irrelevant antigen small peptides and HLA compounds, as a result shows TCR molecules of the present invention and its
His irrelevant antigen is without combination.
All it is incorporated as referring in this application in all documents that the present invention refers to, it is independent just as each document
It is incorporated as with reference to such.In addition, it is to be understood that after the above-mentioned instruction content of the present invention has been read, those skilled in the art can
To be made various changes or modifications to the present invention, these equivalent form of values equally fall within the model that the application appended claims are limited
Enclose.
Claims (35)
- A kind of 1. φt cell receptor（TCR）, it is characterised in that the TCR can be with SYVKVLHHM-HLA A2402 compound knots Close；And 3 complementary determining regions of the TCR α chain variable domains（CDR）For：α CDR1- NYSPAY (SEQ ID NO: 10)α CDR2- IRENEKE (SEQ ID NO: 11)α CDR3- ALQYSGAGSYQLT (SEQ ID NO: 12)；With3 complementary determining regions of the TCR β chain variable domains are：β CDR1- MNHNS (SEQ ID NO: 13)β CDR2- SASEGT (SEQ ID NO: 14)β CDR3- ASSDGPNTEAF (SEQ ID NO: 15)。
- 2. TCR as claimed in claim 1, it is characterised in that it includes TCR α chains variable domains and TCR β chain variable domains, described TCR α chains variable domain be and SEQ ID NO:1 has the amino acid sequence of at least 90% sequence thereto；And/or the TCR β chains Variable domain be and SEQ ID NO：5 have the amino acid sequence of at least 90% sequence thereto.
- 3. TCR as claimed in claim 1, it is characterised in that the TCR includes α chain variable domain amino acid sequence SEQ ID NO: 1。
- 4. TCR as claimed in claim 1, it is characterised in that the TCR includes β chain variable domain amino acid sequence SEQ ID NO: 5。
- 5. TCR as claimed in claim 1, it is characterised in that the TCR is α β heterodimers, and it is constant that it includes TCR α chains Area TRAC*01 and TCR β chain constant regions TRBC1*01 or TRBC2*01.
- 6. TCR as described in claim 5, it is characterised in that the α chain amino acid sequences of the TCR are SEQ ID NO：3 And/or the β chain amino acid sequences of the TCR are SEQ ID NO: 7.
- 7. the TCR as described in any in claim 1-4, it is characterised in that the TCR is solvable.
- 8. TCR as claimed in claim 7, it is characterised in that the TCR is single-stranded.
- 9. TCR as claimed in claim 8, it is characterised in that the TCR is to be connected by α chains variable domain with β chain variable domains by peptide Sequence is connect to be formed by connecting.
- 10. TCR as claimed in claim 9, it is characterised in that the TCR α chains variable region amino acid the 11st, 13,19,21, 76 or 89, and/or α chain J gene small peptides amino acid is reciprocal 3rd, has one or more in 5th reciprocal or reciprocal 7th Individual mutation；And/or the TCR β chains variable region amino acid the 11st, 13,19,21,76,89 or 91, and/or β chain J genes Small peptide amino acid is reciprocal 2nd, has one or more mutation in 4th reciprocal or reciprocal 6th, and wherein amino acid position is compiled Number by the Position Number listed in IMGT (international immunogenetics information system).
- 11. TCR as claimed in claim 10, it is characterised in that the α chains variable domain amino acid sequence of the TCR includes SEQ ID NO:32 and/or TCR β chains variable domain amino acid sequence includes SEQ ID NO:34.
- 12. TCR as claimed in claim 11, it is characterised in that the amino acid sequence of the TCR is SEQ ID NO:30.
- 13. TCR as claimed in claim 7, it is characterised in that the TCR include (a) whole in addition to membrane spaning domain or Part TCR α chains；And all or part of TCR β chains of (b) in addition to membrane spaning domain；And (a) and (b) each self-contained functional variable domain.
- 14. TCR as claimed in claim 13, it is characterised in that cysteine residues the TCR α and β chains constant domain it Between form artificial disulfide bond.
- 15. TCR as claimed in claim 14, it is characterised in that the cysteine that artificial disulfide bond is formed in the TCR is residual Base instead of selected from following one or more groups of sites：The Ser57 of Thr48 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Ser17 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Asp59 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；The Ala19 of Pro89 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s；WithThe Glu20 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1s.
- 16. TCR as claimed in claim 15, it is characterised in that the α chain amino acid sequences of the TCR are SEQ ID NO:26 And/or the β chain amino acid sequences of the TCR are SEQ ID NO:28.
- 17. TCR as claimed in claim 13, it is characterised in that contain between the α chains variable region of the TCR and β chain constant regions Artificial interchain disulfide bond.
- 18. TCR as claimed in claim 17, it is characterised in that half Guang ammonia of artificial interchain disulfide bond is formed in the TCR Sour residue instead of selected from following one or more groups of sites：TRAV the 46th amino acids and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s；TRAV the 47th amino acids and 61 amino acids of TRBC1*01 or TRBC2*01 exons 1s；TRAV the 46th amino acids and the 61st amino acids of TRBC1*01 or TRBC2*01 exons 1s；OrTRAV the 47th amino acids and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1s.
- 19. the TCR as described in claim 17 or 18, it is characterised in that the TCR include α chains variable domain and β chains variable domain with And all or part of β chains constant domain in addition to membrane spaning domain, but it does not contain α chain constant domains, the α chains of the TCR are variable Domain forms heterodimer with β chains.
- 20. TCR as claimed in claim 1, it is characterised in that the α chains of the TCR and/or C- the or N- ends of β chains are combined with Conjugate.
- 21. TCR as claimed in claim 20, it is characterised in that be selected from the group with the TCR conjugates combined：It is detectable Label, therapeutic agent, PK modified parts or its combination.
- 22. TCR as claimed in claim 21, it is characterised in that the therapeutic agent is anti-CD 3 antibodies.
- A kind of 23. multivalent TCR complex, it is characterised in that comprising at least two TCR molecules, and at least one TCR therein Molecule is the TCR any one of claim 1-22.
- 24. a kind of nucleic acid molecules, it is characterised in that the nucleic acid molecules are included any one of coding claim 1-22 The nucleotide sequence of TCR molecules or its complementary series.
- 25. nucleic acid molecules as claimed in claim 24, it is characterised in that it includes the nucleotides sequence of coding TCR α chain variable domains Arrange SEQ ID NO：2 or SEQ ID NO: 33.
- 26. the nucleic acid molecules as described in claim 24 or 25, it is characterised in that it includes the nucleosides of coding TCR β chain variable domains Acid sequence SEQ ID NO：6 or SEQ ID NO: 35.
- 27. nucleic acid molecules as claimed in claim 24, it is characterised in that it includes the nucleotide sequence SEQ of coding TCR α chains ID NO：4 and/or include coding TCR β chains nucleotide sequence SEQ ID NO：8.
- 28. a kind of carrier, it is characterised in that described carrier contains the nucleic acid molecules any one of claim 24-27.
- 29. carrier as claimed in claim 28, it is characterised in that described carrier is viral vector.
- 30. carrier as claimed in claim 29, it is characterised in that described carrier is slow virus carrier.
- 31. a kind of host cell of separation, it is characterised in that contain in described host cell any in claim 28-30 The nucleic acid molecules any one of the claim 24-27 of external source are integrated with carrier or chromosome described in.
- A kind of 32. cell, it is characterised in that the nucleic acid molecules that the cell transduction is had the right any one of requirement 24-27 Or carrier any one of claim 28-30.
- 33. cell as claimed in claim 32, it is characterised in that the cell is T cell or stem cell.
- 34. a kind of pharmaceutical composition, it is characterised in that the composition contains pharmaceutically acceptable carrier and claim Any one of multivalent TCR complex described in TCR, claim 23 or claim 32-33 any one of 1-22 Described cell.
- 35. the multivalent TCR complex or right described in TCR or claim 23 any one of claim 1-22 It is required that the purposes of the cell any one of 32-33, it is characterised in that for preparing the medicine for the treatment of tumour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733891.6A CN106336457B (en) | 2015-10-30 | 2015-10-30 | Identify the φt cell receptor of MAGE A3 antigen small peptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733891.6A CN106336457B (en) | 2015-10-30 | 2015-10-30 | Identify the φt cell receptor of MAGE A3 antigen small peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106336457A CN106336457A (en) | 2017-01-18 |
| CN106336457B true CN106336457B (en) | 2018-03-06 |
Family
ID=57826272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510733891.6A Active CN106336457B (en) | 2015-10-30 | 2015-10-30 | Identify the φt cell receptor of MAGE A3 antigen small peptides |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106336457B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109836490A (en) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | It is a kind of to target the T cell receptor of MAGE-A3, T cell receptor gene modification T cell and its preparation method and application |
| CN109837248A (en) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | A kind of T cell receptor gene modification T cell and its preparation method and application for the targeting MAGE-A3 that TCR is knocked out |
| CN110016074B (en) * | 2018-01-08 | 2021-03-30 | 中国科学院广州生物医药与健康研究院 | MAGE-A3 humanized T cell receptor |
| CN113493505A (en) * | 2020-03-20 | 2021-10-12 | 香雪生命科学技术（广东）有限公司 | High affinity TCR recognizing AFP antigen |
| CN115677846A (en) * | 2021-07-27 | 2023-02-03 | 香雪生命科学技术（广东）有限公司 | High affinity T cell receptors for the antigen SSX2 |
| CN117946245B (en) * | 2023-02-23 | 2024-08-02 | 暨南大学 | T cell receptor for recognizing MAGE-A3 antigen short peptide and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2014206304A1 (en) * | 2013-06-26 | 2014-12-31 | 广州市香雪制药股份有限公司 | High-stability t-cell receptor and preparation method and application thereof |
-
2015
- 2015-10-30 CN CN201510733891.6A patent/CN106336457B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2014206304A1 (en) * | 2013-06-26 | 2014-12-31 | 广州市香雪制药股份有限公司 | High-stability t-cell receptor and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106336457A (en) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106478809B (en) | Identify the TCR of PRAME antigen small peptide | |
| CN106632660A (en) | T cell receptor (TCR) capable of identifying NY-ESO-1 antigen short-peptides | |
| CN106478807B (en) | Identify the T cell receptor of MAGE-A3 | |
| CN106336457B (en) | Identify the φt cell receptor of MAGE A3 antigen small peptides | |
| CN106519019B (en) | Identify the TCR of PRAME antigen | |
| CN106699874B (en) | Identify the T cell receptor of PRAME antigen small peptide | |
| CN106478808B (en) | Identify the T cell receptor of NY-ESO-1 antigen small peptides | |
| CN106188275A (en) | Identify the φt cell receptor of NY-ESO-1 antigen small peptide | |
| CN106749620A (en) | Recognize the φt cell receptor of MAGE A1 antigen small peptides | |
| CN106831978A (en) | Recognize the φt cell receptor of DAGE | |
| CN110343166B (en) | T cell receptor recognizing AFP antigen short peptides | |
| CN106459177B (en) | High affinity ny-eso T cell receptor | |
| CN110343167A (en) | Identify the T cell receptor of SSX2 antigen small peptide | |
| CN106084036A (en) | Identify the φt cell receptor of DAGE small peptide | |
| CN109575121A (en) | Identify the T cell receptor of AFP antigen small peptide | |
| CN106632658B (en) | TCR for recognizing NY-ESO-1 antigen short peptide | |
| CN106279404A (en) | A kind of solvable and stable heterogeneous dimerization TCR | |
| CN108117596A (en) | For the high-affinity TCR of NY-ESO | |
| CN106459179B (en) | Identify the T cell receptor of RHAMM antigen small peptides | |
| CN108264550A (en) | It is a kind of to identify the TCR from PRAME antigen small peptide | |
| CN108948184A (en) | A kind of identification is derived from the T cell receptor of PRAME antigen small peptide | |
| CN113072636B (en) | T cell receptor for identifying AFP and coding sequence thereof | |
| CN109400697A (en) | A kind of TCR of PRAME antigen small peptide and its compositions related of identifying | |
| CN109251243A (en) | A kind of T cell receptor identifying SAGE1 antigen and the nucleic acid for encoding this receptor | |
| CN107987156A (en) | Identify the TCR of SAGE1 antigen small peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171031 Address after: 510663, No. 2, Jinfeng Road, Science Town, Guangzhou hi tech Industrial Development Zone, Guangdong province (first) Applicant after: Guangdong Xiangxue precision medical technology Co Ltd Address before: 510663 Guangdong city of Guangzhou province Luogang District Science City Jinfeng Road No. 2 Applicant before: Guangzhou Xiangxue Pharmaceutical Co., ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210407 Address after: 519031 2715 office building, no.3000 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province Patentee after: Xiangxue Life Science Technology (Guangdong) Co.,Ltd. Address before: 510663 No.2, jinfengyuan Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong Province Patentee before: GUANGZHOU XIANGXUE PHARMACEUTICAL Co.,Ltd. |